Oncology · Clinical trials
Ewing Sarcoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About ewing sarcoma — and why its trials are hard
Ewing sarcoma is an aggressive small round-cell tumour of bone and soft tissue affecting mainly children, adolescents and young adults. It is defined molecularly by a pathognomonic chromosomal translocation, most often EWSR1-FLI1, which generates an oncogenic transcription factor driving the disease. Treatment is multimodal: intensive multi-agent chemotherapy combined with surgery and/or radiotherapy for local control. In North America the standard is interval-compressed (dose-dense) VDC/IE, alternating vincristine, doxorubicin and cyclophosphamide with ifosfamide and etoposide, which cures roughly 70% of patients with localised disease but far fewer with metastatic or relapsed disease. Despite the well-defined fusion oncogene, no targeted therapy has been approved: the EWS-FLI1 fusion protein is a transcription factor long considered undruggable, and multiple targeted strategies have failed in randomised trials. Development is constrained by rarity, the difficulty of drugging a fusion transcription factor, and heavy reliance on paediatric cooperative-group trials. Metastatic and relapsed disease remain the dominant unmet need, with intensified and dose-compressed chemotherapy the principal driver of incremental gains.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| VDC/IE interval-compressed chemotherapy (generic combination (vincristine, doxorubicin, cyclophosphamide / ifosfamide, etoposide)) | 2003 (dose-dense schedule established) | Frontline treatment of localised Ewing sarcoma with local control (surgery/radiotherapy) | COG AEWS0031 (phase 3) | Event-free survival | Compressing cycles from every 3 weeks to every 2 weeks improved 5-year EFS (~65% vs 73%) without added toxicity |
| Vincristine + dactinomycin + cyclophosphamide/doxorubicin (VACD backbone, historical) (generic combination) | 1970s-1980s (foundational) | Historical multi-agent chemotherapy backbone; later augmented with ifosfamide/etoposide | INT-0091 (adding IE to standard chemotherapy) | Event-free survival | Adding ifosfamide/etoposide improved EFS in non-metastatic disease, establishing the modern five-drug regimen |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in ewing sarcoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ganitumab (anti-IGF-1R antibody) — COG AEWS1221 (phase 3, added to interval-compressed chemotherapy) | Did not improve event-free or overall survival in newly diagnosed metastatic Ewing sarcoma | IGF-1R pathway redundancy and compensatory signalling; earlier single-agent IGF-1R antibodies (figitumumab, R1507) gave only sporadic, non-durable responses |
| IGF-1R monoclonal antibodies (figitumumab, R1507) — Phase 2 relapsed/refractory studies | Low overall response rates (~10%) with short duration; no approval | Rapid resistance, lack of predictive biomarker to select responders |
Choosing the right endpoint
Primary endpoints that matter in ewing sarcoma trials
- Event-free survival (EFS) — Primary frontline endpoint in cooperative-group trials (AEWS0031, AEWS1221); captures relapse, progression, second cancer or death
- Overall survival (OS) — Definitive endpoint; sharply worse in metastatic and relapsed disease, defining the core unmet need
- Objective response rate (ORR) — Used in relapsed/refractory and early-phase targeted-agent studies to screen for activity
- Local control rate — Reflects success of surgery and/or radiotherapy integrated with chemotherapy
- Progression-free survival (PFS) — Endpoint in relapsed-setting regimen trials where cure is unlikely
How iNGENū runs ewing sarcoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Ewing Sarcoma clinical trials — FAQs
If Ewing sarcoma has a known fusion gene, why is there no targeted drug?
What is interval-compressed chemotherapy?
Why did IGF-1R inhibitors fail?
Ready to discuss your ewing sarcoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal